<DOC>
	<DOCNO>NCT02902666</DOCNO>
	<brief_summary>The purpose study evaluate bioequivalence new paracetamol 1000 mg/codeine 30 mg formulation vs. market reference Co-efferalgan® 500 mg/30 mg term rate extent absorption , administer single oral dose ( one tablet new A.C.R.A.F . formulation vs. two tablet reference formulation Co-efferalgan® ) healthy male female volunteer , fast condition , two consecutive study period .</brief_summary>
	<brief_title>Bioequivalence Study One Tablet Paracetamol 1000 mg + Codeine 30 mg vs. Two Tablets Paracetamol 500 mg + Codeine 30 mg</brief_title>
	<detailed_description />
	<mesh_term>Codeine</mesh_term>
	<mesh_term>Acetaminophen</mesh_term>
	<criteria>1 . Informed consent : sign write informed consent inclusion study 2 . Sex Age : males/females , 1855 year old inclusive 3 . Body Mass Index ( BMI ) : 18.530 kg/m2 inclusive 4 . Vital sign : systolic blood pressure ( SBP ) 100139 mmHg , diastolic blood pressure ( DBP ) 5089 mmHg , heart rate ( HR ) 5090 bpm , measure 5 min rest sit position 5 . Full comprehension : ability comprehend full nature purpose study , include possible risk side effect ; ability cooperate investigator comply requirement entire study 6 . Tobacco : nonsmoker exsmokers least 6 month 7 . Contraception fertility ( female ) : female childbearing potential must use least one follow reliable method contraception : 1 . Hormonal oral , implantable , transdermal , injectable contraceptive least 2 month screen visit 2 . A nonhormonal intrauterine device [ IUD ] female condom spermicide contraceptive sponge spermicide diaphragm spermicide cervical cap spermicide least 2 month screen visit 3 . A male sexual partner agree use male condom spermicide 4 . A sterile sexual partner . Female participant nonchildbearing potential postmenopausal status least 1 year admit . For female subject , pregnancy test result must negative screening . 1 . Electrocardiogram ( 12leads , supine position ) : clinically significant abnormality 2 . Physical finding : clinically significant abnormal physical finding could interfere objective study 3 . Laboratory analysis : clinically significant abnormal laboratory value indicative physical illness 4 . Allergy : ascertain presumptive hypersensitivity active principle ( paracetamol and/or codeine ) and/or formulation ' ingredient related drug , namely nonsteroidal antiinflammatory agent and/or opioid derivative ; history anaphylaxis drug allergic reaction general , investigator considers may affect outcome study 5 . Diseases : significant history renal , hepatic , gastrointestinal , genitourinary , cardiovascular , respiratory ( include allergic asthma , allergic chronic bronchitis pulmonary disease ) , skin , haematological , endocrine neurological disease may interfere aim study 6 . Medications : medication , include counter ( OTC ) medication herbal remedy 2 week start study . Hormonal contraceptives female allow 7 . Investigative drug study : participation evaluation investigational product 3 month study . The 3month interval calculate time first calendar day month follow last visit previous study first day present study 8 . Blood donation : blood donation 3 month study 9 . Drug , alcohol , caffeine : history drug , alcohol [ &gt; 1 drink/day female &gt; 2 drinks/day male , define accord USDA Dietary Guidelines 2010 ] , caffeine ( &gt; 5 cup coffee/tea/day ) abuse 10 . Drug test : positive result drug test screen day1 11 . Alcohol test : positive alcohol breath test day 1 12 . Diet : abnormal diet ( &lt; 1600 &gt; 3500 kcal/day ) substantial change eat habit 4 week study ; vegetarian 13 . Pregnancy ( female ) : positive miss pregnancy test screen day 1 , pregnant lactating woman</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Bioequivalence</keyword>
	<keyword>Paracetamol 1000 mg/codeine 30 mg</keyword>
	<keyword>Co-efferalgan 500 mg/30 mg</keyword>
</DOC>